The story of Viagra presents a intricate picture for shareholders. While the initial introduction generated significant Gambling gains, the expiration of its intellectual property protection opened the floodgates to off-brand competitors, dramatically eroding revenue. This presents a particular challenge for pharmaceutical companies depending on re

The story of Viagra, and its creator copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in income, its intellectual property lapse created a flood of knock-off medications, significantly diminishing its market share . While some businesses may try to capitalize on similar conditions , the present